Unfractionated Heparin for the Treatment of Venous Thromboembolism: Best Practices and Areas of Uncertainty

被引:21
作者
Cuker, Adam [1 ,2 ]
机构
[1] Univ Penn, Dept Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
关键词
heparin; unfractionated heparin; venous thromboembolism; dosing; laboratory monitoring; PARTIAL THROMBOPLASTIN TIME; MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; CONTINUOUS INTRAVENOUS HEPARIN; ACUTE PULMONARY-EMBOLISM; MYOCARDIAL-INFARCTION; ANTICOAGULANT-THERAPY; SUBCUTANEOUS HEPARIN; INITIAL TREATMENT; ANTITHROMBIN-III;
D O I
10.1055/s-0032-1319770
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nearly 100 years after its discovery, unfractionated heparin (UFH) remains a widely used anticoagulant for the treatment of venous thromboembolism (VTE) and several other thrombotic and prothrombotic conditions. Decades of experience and investigation have contributed to our knowledge of this agent, but crucial questions regarding its optimal use in clinical practice remain unanswered. This review will critically examine the evidence for dosing and laboratory monitoring of UFH in the management of VTE, and highlight areas of uncertainty and future research.
引用
收藏
页码:593 / 599
页数:7
相关论文
共 64 条
[1]  
Adcock DM, 1997, AM J CLIN PATHOL, V107, P105
[2]   The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin [J].
Anand, S ;
Ginsberg, JS ;
Kearon, C ;
Gent, M ;
Hirsh, J .
ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (15) :1677-1681
[3]   Recurrent venous thrombosis and heparin therapy -: An evaluation of the importance of early activated partial thromboplastin times [J].
Anand, SS ;
Bates, S ;
Ginsberg, JS ;
Levine, M ;
Buller, H ;
Prins, M ;
Haley, S ;
Kearon, C ;
Hirsh, J ;
GEnt, M .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (17) :2029-2032
[4]   ANTICOAGULANT PROPERTIES OF HEPARIN FRACTIONATED BY AFFINITY CHROMATOGRAPHY ON MATRIX-BOUND ANTITHROMBIN-3 AND BY GEL-FILTRATION [J].
ANDERSSON, LO ;
BARROWCLIFFE, TW ;
HOLMER, E ;
JOHNSON, EA ;
SIMS, GEC .
THROMBOSIS RESEARCH, 1976, 9 (06) :575-583
[5]  
[Anonymous], 1999, J GERONTOL B, V353, P429
[6]  
[Anonymous], 1937, ACTA CHIR SCAND
[7]  
Ansell J., 2012, THROMB HAEMOST, V107
[8]   Hirudin in acute myocardial infarction - Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial [J].
Antman, EM .
CIRCULATION, 1996, 94 (05) :911-921
[9]   Guidelines on the use and monitoring of heparin [J].
Baglin, T ;
Barrowcliffe, TW ;
Cohen, A ;
Greaves, M .
BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 (01) :19-34
[10]  
BAIN B, 1980, AM J CLIN PATHOL, V74, P668